Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Multiple Myeloma 40Neoplasms, Plasma Cell 13Lymphoma 12Neuroblastoma 10Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Immunoglobulin Light-chain Amyloidosis 8Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5Uveal Melanoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia 3Amyloidosis 3Neoplasm Metastasis 2Hodgkin Disease 2Ganglioneuroblastoma 2Venentoclax 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma 1Retinoblastoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms by Histologic Type 1

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Venentoclax × Melphalan × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡